Biomea Fusion, INC 8-K filings

NASDAQ

1 Apr 2024

BMEA

8-K: Biomea Fusion Reports Positive Clinical Data and Year-End Financials, Advancing Diabetes and Oncology Programs

Biomea Fusion announced positive clinical data for its diabetes programs and provided a financial update for the fourth quarter and full year 2023, highlighting progress in both metabolic disease and oncology pipelines.

NASDAQ

7 Mar 2024

BMEA

Biomea Fusion, INC

8-K: Biomea Fusion's BMF-219 Shows Durable Glycemic Control in Type 2 Diabetes Patients

Biomea Fusion's BMF-219 demonstrates a durable reduction in HbA1c levels and improved pancreatic function in type 2 diabetes patients, even after the treatment period.